EID: Bridging the Gap Between Humans and Wildlife

Sometime in the 1980s, the emerging infectious disease (EID) movement began. The "emerging" label had been used earlier, but a series of high-profile disease outbreaks in the 1980s, combined with perceived funding gaps, began to galvanize the field. A book by Richard Krause of the National Institutes of Health1 formed part of the initial thrust. Published in the same year as the recognition of AIDS, it commented on the alarming phenomenon of antibiotic-resistant microbes. Further threats surfac

Written byPeter Daszak
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share



Sometime in the 1980s, the emerging infectious disease (EID) movement began. The "emerging" label had been used earlier, but a series of high-profile disease outbreaks in the 1980s, combined with perceived funding gaps, began to galvanize the field. A book by Richard Krause of the National Institutes of Health1 formed part of the initial thrust. Published in the same year as the recognition of AIDS, it commented on the alarming phenomenon of antibiotic-resistant microbes. Further threats surfaced: Legionnaire's disease, toxic shock syndrome, multiple-drug resistance in a host of important pathogens, Lyme disease, and others.

The year 1992 saw the publication of an Institute of Medicine treatise on emerging infections,2 and a special section in Science talked about a "post-antimicrobial era," tuberculosis as a "reemergent killer," and the "crisis in antibiotic resistance." This was rapidly followed by Emerging Viruses3 by Stephen S. Morse of Rockefeller University, and another Science section included ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies